EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, CanBas Co's Enterprise Value is 円6,456.54 Mil.
CanBas Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was 円-1,073.49 Mil. Therefore, CanBas Co's EV-to-EBIT for today is -6.01.
The historical rank and industry rank for CanBas Co's EV-to-EBIT or its related term are showing as below:
TSE:4575'
s EV-to-EBIT Range Over the Past 10 Years
Min: -32.49 Med: -7.87 Max: -2.09
Current: -6.01
During the past 13 years, the highest EV-to-EBIT of CanBas Co was -2.09. The lowest was -32.49. And the median was -7.87.
TSE:4575's EV-to-EBIT is ranked worse than 100% of 443
companies
in the Biotechnology industry
Industry Median: 8.19
vs TSE:4575: -6.01
The historical data trend for CanBas Co's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CanBas Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CanBas Co's EV-to-EBIT Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CanBas Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where CanBas Co's EV-to-EBIT falls into.
CanBas Co EV-to-EBIT Calculation
CanBas Co's EV-to-EBIT for today is calculated as:
CanBas Co's current Enterprise Value is 円6,456.54 Mil.
CanBas Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-1,073.49 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CanBas Co (TSE:4575) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
CanBas Co's Enterprise Value for the quarter that ended in Dec. 2023 was 円14,521.70 Mil.
CanBas Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-1,073.49 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CanBas Co EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of CanBas Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
CanBas Co Ltd focuses on the discovery and development of novel oncology drugs targeting the cell cycle. Its product, CBP501 the anticancer drug candidate is a modified synthetic peptide which enhances the efficacy of cisplatin without adding toxicity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSE:4575 has been successfully added to your 